SYF0e9beff2ea5e4aa2a025faefed1c74cfRegistry ID: 2025-524741-28-00|Not Yet RecruitingPhase 4
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
Amsterdam UMC StichtingCTIS (EMA)
Loading search results
interventional
N/A
1 country
1
To evaluate the feasibility and safety of gradual interval prolonging of biologics during ~1 year in patients with severe asthma
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 19, 2026
Actual (reported)Maintained asthma control after ~1 year of study participation with at least one step of interval prolongation. Asthma control is defined as not more than one additional exacerbation compared to baseline frequency during ~1 year and a ACQ < 2.0 at the last study visit. An exacerbation is defined as an acute worsening of symptoms lasting more than 48 hours, as assessed by the treating physician.
Exacerbation frequency per year.
Blood eosinophile count in *10^9 cells per liter
FeNO in parts per billion (ppb)
Forced Expiratory Volume in 1 second (FEV1)
Forced Vital Capacity (FVC)
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Nucala 100 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
CINQAERO 10 mg/mL concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry recordFormulated product
Dupixent 200 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Fasenra 30 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Nucala 100 mg solution for injection in pre-filled pen
Named ingredient: mepolizumab
View registry recordCINQAERO 10 mg/mL concentrate for solution for infusion
Named ingredient: reslizumab
View registry recordDupixent 200 mg solution for injection in pre-filled pen
Named ingredient: dupilumab
View registry recordFasenra 30 mg solution for injection in pre-filled pen
Named ingredient: benralizumab
View registry recordDupixent 300 mg solution for injection in pre-filled pen
Named ingredient: dupilumab
View registry recordTezspire 210 mg solution for injection in pre-filled pen
Named ingredient: tezepelumab
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Amsterdam UMC Stichting
Amsterdam, 1081 HV, Netherlands
B. Hilvering
First Submitted
February 19, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Formulated product
Dupixent 300 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
Formulated product
Tezspire 210 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordContact the study team to confirm eligibility.